Myelodysplastic syndromes
Strebel, U.
Therapeutische Umschau. Revue Therapeutique 45(2): 100-105
1988
ISSN/ISBN: 0040-5930 PMID: 3358242 Document Number: 322899
Document emailed within 1 workday
Related Documents
Tassin, F.; Hermanne, J.P.; Schaaf-Lafontaine, N.; Herens, C.; Thiry, A.; Paulus, J.M.; Boniver, J.; Fillet, G. 1998: Myelodysplastic syndromes: preleukemic syndromes Revue Medicale de Liege 53(6): 357-362Dusek, J.; Bednár, B.; Dorazilová, V.; Fakan, F.; Kerekes, Z. 1990: Myelodysplastic syndromes Ceskoslovenska Patologie 26(3): 129-134
Sizoo, W.; Hagenbeek, A.; Löwenberg, B.; van 't Veer, M.B.; Sintnicolaas, K. 1987: Myelodysplastic syndromes Nederlands Tijdschrift Voor Geneeskunde 131(38): 1658-1661
Guisasola Zulueta, M.C.; Gilsanz Fernández, C.; Tintó del Val, J.A.; García de la Fuente, A. 1986: Myelodysplastic syndromes Revista Clinica Espanola 179(4): 190-195
Lishner, M.; Ravid, M. 1988: Myelodysplastic syndromes Harefuah 115(3-4): 73-76
Doll, D.C.; List, A.F. 1992: Myelodysplastic syndromes: introduction Seminars in Oncology 19(1): 1-3
Tohyama, K. 2012: Treatment of myelodysplastic syndromes (MDS) Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 2): 367-372
Carvajal Méndez, I.; García Vadillo, J.A.; Herranz Varela, A.; González Alvaro, I.; Casado Montero, F.; Castañeda Sanz, S. 1996: Polyarthritis associated with myelodysplastic syndromes Revista Clinica Espanola 196(8): 539-541
Solary, E.; Fontenay, M.ël. 2010: Myeloproliferative/myelodysplastic syndromes La Revue du Praticien 60(10): 1413-1415
Turtureanu-Hanganu, E. 2004: The point on myelodysplastic syndromes Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 108(1): 9-16
Prieto, F.; Carbonell, F.; Badía, L.; Castel, V.; Pérez Sirvent, M.L. 1985: Cytogenetics in the study of myelodysplastic syndromes Sangre 30(4-C): 669-679
Jonveaux, P.; Fenaux, P.; Quiquandon, I.; Pignon, J.M.; Laï, J.L.; Loucheux-Lefebvre, M.H.; Goossens, M.; Bauters, F.; Berger, R. 1991: Mutations in the p53 gene in myelodysplastic syndromes Oncogene 6(12): 2243-2247
Luraschi, A.; Saglietti, G.; Fedeli, P.; Gioria, A.; Della Vedova, A.; Ferrari, V.; Borgotti, P. 1994: Immunological indices in myelodysplastic syndromes Minerva Medica 85(4): 145-153
Neuwirtová, R.; Mociková, K.; Jelínek, J.; Musilová, J.; Havlícek, F.; Adamkov, M.; Michalová, K.; Cermák, J.; Jonásová, A.; Smolíková, A.; Straub, J.; Tothová, E.; Voglová, J.; Vozobulová, V.; Waltrová, L. 1997: Mixed myelodysplastic and myeloproliferative syndromes Casopis Lekaru Ceskych 136(23): 724-729
Atallah, E.; Garcia-Manero, G. 2007: Use of hypomethylating agents in myelodysplastic syndromes Clinical Advances in Hematology and Oncology: H&o 5(7): 544-552
Kim, H.; Garcia-Manero, G. 2008: Management of myelodysplastic syndromes: just the beginning Oncology 22(12): 1360; 1363, 1368
Pozzato, G.; Franzin, F.; Moretti, M.; Campanacci, L. 1992: Danazol therapy in myelodysplastic syndromes Haematologica 77(1): 96
Alessandrino, E.P.; Lazzarino, M.; Morra, E.; Bernasconi, P.; Colombo, A.; Bonfichi, M.; Caldera, D.; Bernasconi, C. 1990: Alpha-interferon and myelodysplastic syndromes Haematologica 75(Suppl 4): 51-55
Hellström-Lindberg, E. 1999: Treatment of adult myelodysplastic syndromes International Journal of Hematology 70(3): 141-154
Pu, Q. 2003: Further standardization of classification of myelodysplastic syndromes Zhonghua Nei Ke Za Zhi 42(5): 289-291